Beijing's 220 health centers have since Friday vaccinated 73,537 people, with no major side effects detected, said Gao Xiaojun, a spokesman for the Beijing Health Commission, at a news conference on Sunday.
The inactivated vaccine, which got the approval from the National Medical Products Administration (NMPA), is developed by the Beijing Biological Products Institute Co., Ltd. under the China National Biotec Group (CNBG), which is affiliated with Sinopharm.
The interim results of its phase-3 clinical trials show 79.34 percent efficacy against COVID-19, meeting the standards of the World Health Organization and the NMPA, according to a press conference by the State Council joint prevention and control mechanism against COVID-19.This vaccine will be provided free of charge to all Chinese people.
Currently, health centers don't accept individual vaccination reservations. Individuals going abroad for personal reasons can apply for the shot at their residential community service centers.
Groups that are not suitable to receive the vaccines include pregnant women, lactating women and patients with some diseases. These patients are those in the acute stage of fever and infection, suffering from immune deficiency or immune disorder, having severe liver or kidney diseases, having uncontrolled hypertension, diabetic complications or malignant tumors.
Currently, people in the age group from 18 to 59 are arranged to receive the vaccination, and people not in the age group should wait for further data of clinical trials to know whether they could be vaccinated.